Company Description
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients.
The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.
The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020.
The company was incorporated in 2003 and is based in Needham, Massachusetts.
| Country | United States |
| IPO Date | Jul 27, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. |
Contact Details
Address: 117 Kendrick Street Needham, Massachusetts United States | |
| Website | https://www.candeltx.com |
Stock Details
| Ticker Symbol | CADL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001841387 |
| CUSIP Number | 137404109 |
| ISIN Number | US1374041093 |
| Employer ID | 52-2214851 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | President, Chief Executive Officer & Director |
| Charles Schoch | Interim Chief Financial Officer, Principal Accounting Officer, Treasurer & Secretary |
| Ileen B. Winick | Chief People Officer |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical & Development Officer |
| Dr. William Garrett Nichols M.D., M.S. | Chief Medical Officer |
| Susan Stewart J.D., L.L.M. | Chief Regulatory Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 12, 2024 | 424B5 | Filing |
| Dec 11, 2024 | 8-K | Current Report |
| Dec 06, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Nov 27, 2024 | 4 | Filing |
| Nov 21, 2024 | 4 | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |